Topoisomerase IIα gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer

Breast

Volumn 17, Issue 5, 2008, Pages 506-511

  Orlando, Laura ^a   Del Curto, Barbara ^a   Gandini, Sara ^a   Ghisini, Raffaella ^a   Pietri, Elisabetta ^a   Torrisi, Rosalba ^a   Balduzzi, Alessandra ^a   Cardillo, Anna ^a   Dellapasqua, Silvia ^a   Veronesi, Paolo ^a   Viale, Giuseppe ^a   Goldhirsch, Aron ^a   Colleoni, Marco ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Breast cancer; Predictive markers; Preoperative chemotherapy; Topoisomerase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CISPLATIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; UNCLASSIFIED DRUG; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER REGRESSION; CHROMOSOME 17; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; BREAST TUMOR; DRUG RESISTANCE; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; REMISSION; RETROSPECTIVE STUDY;

ADULT; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 53149089444     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.03.007     Document Type: Article

References (33)

1. Mauriac L., Macgrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: An unicentre randomized trial with a 124-months median follow-up. Institute Bergonie Bordeaux Groupe Sein (IBBGS). Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 1 (1999) 47-52
2. Fisher B., Briant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 (1998) 2672-2685
3. Powels T.J., Hickish T.F., Makris A., et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13 3 (1995) 547-552
4. McGrogan G., Mauriac L., Durand M., et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immuno-histochemical detection of hormonal receptors, p53, c-erbB2, Mib-ps2 and GST pi. Br J Cancer 74 (1996) 1458-1465
5. Faneyte I.F., Scharma J.G., Peterse J.L., Remijnse P.L., Rodenhius S., and van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88 (2003) 406-412
6. Colleoni M., Viale G., Zahrieh D., et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10 (2004) 6622-6628
7. Kellner U., Sehested M., Jensen P., Gieseler F., and Rudolph P. Culprit and victim-DNA topoisomerase II. Lancet Oncol 3 (2002) 235-243
8. Berger J.M., Gamblin S.J., Harrison S.C., and Wang J.C. Structure and mechanism of DNA topoisomerase II. Nature 379 (1996) 225-232
9. Gudkov A.V., Zelnick C.R., Kazarov A.R., et al. Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90 (1993) 3231-3235
10. Zhou Z., Zwelling L., Kawakami Y., et al. Adenovirus-mediated human topoisomerase II alpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells. Cancer Res 59 (1999) 4618-4624
11. Tanner M., Isola J., Wiklund T., et al. Topoisomerase II gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in Her2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9410. J Clin Oncol 24 (2006) 2428-2436
12. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of TOPO IIa amplification and deletion as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate and fluorouracil or cyclophosphamide, epirubicin and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 (2005) 7483-7490
13. Di Leo A., Gancberg D., Larsimont D., et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node- positive breast cancer patients randomly treated either with an anthracycline- based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8 (2002) 1107-1116
14. Ellis P.A., Smith I.E., Detre S., et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 48 (1998) 107-116
15. Chang J., Powles T.J., Allred D.C., et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Cancer 17 (1999) 3058-3063
16. Fisher E.R., Wang J., Bryant J., Fisher B., Mamounas E., and Wolmark N. Pathobiology of preoperative findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18. Cancer 95 (2002) 681-695
17. Ayers M., Symmans W.F., Stec J., et al. Gene expression profiles predict complete pathological response to neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22 (2004) 2284-2293
18. Gianni L., Zambetti M., Clark K., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23 (2005) 7265-7277
19. Hess K.R., Anderson K., Symmans W.F., et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin and cyclophosphamide in breast cancer. J Clin Oncol 24 (2006) 4236-4244
20. Pritchard K.I., Shepherd L.E., O'Malley F.P., et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 18 (2006) 2103-2111
21. Nelson N.J. Can HER2 status predict response to cancer therapy?. J Natl Cancer Inst 92 (2000) 366-367
22. McNeil C. Using Her2 to choose chemotherapy in breast cancer: is it ready for the clinic?. J Natl Cancer Inst 91 (1999) 110-112
23. Pegram M.D., Finn R.S., Arzoo K., Beryt M., Pietras R.J., and Slamon D.J. The effect of Her2/neu overexpression on chemotherapy drug sensitivity in human breast and ovarian cancer cells. Oncogene 15 (1997) 537-547
24. Jacobson K.K., Morrison L.E., Henderson B.T., et al. Gene copy mapping of the ERBB2/TOP2A region in breast cancer. Genes Chromosome Cancer 40 (2004) 19-31
25. Jarvinen T.A., Holli K., Kuukasjarvi T., and Isola J.J. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubucin chemotherapy in advanced breast cancer. Br J Cancer 77 (1998) 2267-2273
26. Murthy S.K., Magliocco A.M., and Demetrick D.J. Copy number analysis of c-erbB2 (HER2/neu) and topoisomerase IIa gene in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization. Arch Pathol Lab Med 129 (2005) 39-46
27. McGrogan G., Rudolph P., de Mascarel I., et al. DNA topoisomerase IIa expression and the response to primary chemotherapy in breast cancer. Br J Cancer 89 (2003) 666-671
28. Martin Richard M., Munoz M., Albanell J., et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology 66 (2004) 388-394
29. Coon J.S., Marcus E., Gupta-Burt S., et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline based therapy in locally advanced breast cancer. Clin Cancer Res 8 (2002) 1061-1067
30. Rody A., Karn T., Gatje R., et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin and cyclophosphamide within GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 16 (2007) 86-93
31. Petit T., Wilt M., Velten M., et al. Comparative value of tumor grade, hormonal receptors, Ki-67, Her-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer 40 (2004) 205-211
32. Lal P., Salazar P.A., Ladanyi M., and Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 5 (2003) 155-159
33. Jarvinen T.A., and Liu E.T. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase II alpha (TOP2A) genes-molecular basis for combination chemotherapy in cancer. Curr Cancer Drug Targets 6 (2006) 579-602